Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD

Background: Both tiotropium (T) and olodaterol (O) monotherapies improve exercise endurance in patients with chronic obstructive pulmonary disease (COPD). Objective: To evaluate the effects of T+O fixed-dose combination on exercise endurance in patients with GOLD 2 – 3 COPD after 12 weeks. Methods: TORRACTO (NCT01525615) was a 12-week, double-blind, parallel-group, placebo-controlled, Phase III study. Patients with GOLD 2 – 3 COPD received T+O (5/5 or 2.5/5 µg) once daily via Respimat Soft Mist inhaler, or placebo. Primary end point was endurance time (ET) during constant work-rate cycle ergometry to symptom lim…